Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events

a technology of thrombotic events and mixtures, which is applied in the direction of sugar derivates, biocide, organic chemistry, etc., can solve the problems of limited effectiveness of heparin use, heterogeneous products, and difficult to assess the contribution of each species to the activity of heparin, so as to improve the therapeutic potential, improve the effect of dose administration and excellent bioavailability

Inactive Publication Date: 2005-06-14
AVENTIS PHARMA SA (US)
View PDF47 Cites 53 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016]In addition, in humans, the mixtures of the invention display excellent bioavailability, as measured by the anti-Xa activity. Thus, this value is approximately 30 <?delete-start id="DEL-S-00001" date="20050614" ?>IU<?delete-end id="DEL-S-00001" ?> <?insert-start id="INS-S-00001" date="20050614" ?>% for heparin, but is approximately 90 <?delete-start id="DEL-S-00002" date="20050614" ?>IU<?delete-end id="DEL-S-00002" ?> <?insert-start id="INS-S-00002" date="20050614" ?>% for the mixtures of the invention. This too is desirable in that it permits the doses administered to be reduced and the therapeutic potential to be improved.
[0018]Another characteristic of the mixtures according to the invention is their low clearance compared with other products and with mature heparin. As a result of their chemical structure, their molecular weight or their sulfate content, these mixtures effectively display a particular pronounced resistance to degradation (desulfation, hydrolysis) and to elimination, which further enhances their therapeutic availability.
[0020]Too, these preparations also exhibit a reduced sensitivity to serum factors, which enhances their duration of action in vivo and permits them to be used in low doses.

Problems solved by technology

However, in their native state, the heparins present a number of disadvantages which limit the extent of their effective use.
Indeed, the marked anticoagulant activity of the heparins can cause hemorrhaging, and their sensitivity to certain serum factors such as pf4 mandates the administration of relatively large doses thereof.
However, one of the principal difficulties associated with the heparins is that they are very heterogeneous products.
Therefore, it is difficult to assess the contribution of each of the species to the activity of heparin, to determine the behavior of these species during depolymerization and, finally, to control the structure of such species and their respective proportions in the final products.
For these reasons, it has not to date been possible to resolve completely satisfactorily the difficulties indicated above.
In particular, the processes described in the prior art, and especially in EP 40,144, do not permit the production of mixtures possessing the requisite pharmacological properties for improved therapeutic applications, namely, a sufficiently long plasma half-life, a fairly high absorption rate, a high bioavailability or, alternatively, a low clearance.
Nonetheless, these final mixtures continue to elicit a residual hemorrhagic effect, or too low an antithrombotic response.
This is reflected in the above publication, where the authors conclude, “We do not know what combination of the properties of heparin is optimal.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0067]This example illustrates the preliminary step of treatment of heparin sodium, enabling the content of impurities of the chondroitin sulfate and heparan sulfate type to be reduced.

[0068]Methanol (80 ml) was added to commercial heparin (sodium salt) (10 g) dissolved in water (100 ml) containing sodium chloride (3 g). After precipitation, the product obtained was filtered off, rinsed and then dried. The degree of purity of the heparin sodium thereby obtained was measured by steric exclusion liquid chromatography, using two columns in series, marketed under the trademarks TSK 2000SW (60×0.75 cm) and TSK 3000 SW (60×0.75 cm), coupled to a UV detector adjusted to 206 nm. The mobile phase employed was 0.5M aqueous sodium sulfate solution flowing at a rate of 1 ml.min−1. The test sample was compared with a control heparin containing dermatan sulfate (2%).

[0069]Under the conditions described above, the heparin obtained contained less than 2% of dermatan sulfate.

example 2

[0070]This example illustrates the preparation of the quaternary ammonium salt of heparin.

[0071]A solution of benzethonium chloride (25 g) in water (125 ml) was added to a solution of heparin sodium (10 g) prepared as in Example 1, containing less than 2% of dermatan sulfate, in water (100 ml). The product obtained at room temperature was then filtered off, washed with water and thereafter dried.

[0072]In identical manner, the benzethonium salt of a heparin which has not been subjected to the treatment of Example 1 was prepared.

example 3

[0073]This example illustrates the preparation and properties of the mixtures according to the invention.

1. Esterification:

[0074]Benzyl chloride (15 ml) was added to a solution of benzethonium heparinate (15 g), preliminarily treated according to the procedure of Example 1, in methylene chloride (75 ml). The solution was heated to a temperature of 35° C., which was maintained for 25 hours. A 10% solution (90 ml) of sodium acetate in methanol was then added, the mixture was filtered and the product was washed in methanol and dried. Heparin benzyl ester (6.5 g) was thereby obtained in the form of a sodium salt, the degree of esterification of which, determined as described above, was 13.3%.

2. Depolymerization:

[0075]The heparin benzyl ester (10 g) obtained above in the form of a sodium salt was dissolved in water (250 ml). To this solution, heated to 62° C., sodium hydroxide (0.9 g) was added. The temperature was maintained for 1 hour, 30 minutes, at 62° C. the reaction mixture was the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Login to View More

Abstract

Heterogeneous intimate admixtures of sulfated heparinic polysaccharides, well suited for the prophylaxis / treatment of acute thrombotic episodes in a human patient, comprise immixture of sulfated polysaccharides having a weight average molecular weight less than that of heparin and which include from 9% to 20% of polysaccharide chains having a molecular weight less than 2,000 daltons and from 5% to 20% of polysaccharide chains having a molecular weight greater than 8,000 daltons, the ratio between the weight average molecular weight and the number average molecular weight thereof ranging from 1.3 to 1.6.

Description

[0001]This application is a continuation, of application Ser. No. 07 / 721,315, filed Jun. 26, 1991, now abandoned.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present invention relates to novel mixtures of low molecular weight (LMW) polysaccharides and, more especially, to novel mixtures of LMW heparinic polysaccharides will adopted for the prevention of venous thromboses.[0004]2. Description of the Prior Art[0005]The heparins are biologically active agents of the glycosaminoglycan family, extracted from natural sources, and have valuable anticoagulant and antithrombotic properties. In particular, they are useful in the treatment of postoperative venous thromboses. However, in their native state, the heparins present a number of disadvantages which limit the extent of their effective use. Indeed, the marked anticoagulant activity of the heparins can cause hemorrhaging, and their sensitivity to certain serum factors such as pf4 mandates the administration of rel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C08B37/00
CPCC08B37/0078
Inventor DEBRIE, ROGER
Owner AVENTIS PHARMA SA (US)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products